GT Biopharma Q2 EPS $(2.17) Down From $(1.49) YoY
Portfolio Pulse from Benzinga Newsdesk
GT Biopharma (NASDAQ:GTBP) reported a Q2 EPS loss of $(2.17), a 45.64% decrease from the $(1.49) loss per share in the same period last year.
August 14, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
GT Biopharma reported a significant increase in quarterly losses, with Q2 EPS at $(2.17) compared to $(1.49) last year, indicating financial challenges.
The significant increase in quarterly losses suggests financial difficulties, which is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100